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ABSTRACT 
The long-term objective of this project is to utilize the I-domain protein for the α-subunit of 
LFA-1 to target drugs to lymphocytes by binding to ICAM receptors on the cell surface. The 
short-term goal is to provide proof-of-concept that I-domain conjugated to small molecules 
can still bind to and uptake by ICAM-1 on the surface of lymphocytes (i.e., Raji cells). To 
accomplish this goal, the I-domain protein was labeled with FITC at several lysine residues to 
produce the FITC-I-domain and CD spectroscopy showed that the FITC-I-domain has a 
secondary structure similar to that of the parent I-domain. The FITC-I-domain was taken up 
by Raji cells via receptor-mediated endocytosis and its uptake can be blocked by anti-I-
domain mAb but not by its isotype control. Antibodies to ICAM-1 enhance the binding of I-
domain to ICAM-1, suggesting it binds to ICAM-1 at different sites than the antibodies. The 
results indicate that fluorophore modification does not alter the binding and uptake properties 
of the I-domain protein. Thus, I-domain could be useful as a carrier of drug to target ICAM-
1-expressing lymphocytes. 
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